{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:33:08Z","timestamp":1707525188707},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,18]]},"DOI":"10.7759\/cureus.43695","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T12:54:05Z","timestamp":1692363245000},"source":"Crossref","is-referenced-by-count":1,"title":["Hidradenitis Suppurativa: A Literature Review Comparing Current Therapeutic Modalities"],"prefix":"10.7759","author":[{"given":"Urvashi","family":"Rathod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja N","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaumikkumar Mukeshbhai","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brinda","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chintankumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth Kamal","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyansh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis","volume":"157","author":"Jfri A","year":"2021","unstructured":"Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021, 157:924-31. 10.1001\/jamadermatol.2021.1677","journal-title":"JAMA Dermatol"},{"key":"ref2","article-title":"Hidradenitis suppurativa: a review with a focus on treatment data","volume":"20","author":"Barlev D","year":"2015","unstructured":"Barlev D, Eisen DB, Alikhan A. Hidradenitis suppurativa: a review with a focus on treatment data. Skin Therapy Lett. 2015, 20:1-8.","journal-title":"Skin Therapy Lett"},{"key":"ref3","article-title":"Finasteride in hidradenitis suppurativa: a \"male\" therapy for a predominantly \"female\" disease","volume":"9","author":"Khandalavala BN","year":"2016","unstructured":"Khandalavala BN, Do MV. Finasteride in hidradenitis suppurativa: a \"male\" therapy for a predominantly \"female\" disease. J Clin Aesthet Dermatol. 2016, 9:44-50.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.05.036","article-title":"Altered skin and gut microbiome in hidradenitis suppurativa","volume":"142","author":"McCarthy S","year":"2022","unstructured":"McCarthy S, Barrett M, Kirthi S, et al.. Altered skin and gut microbiome in hidradenitis suppurativa. J Invest Dermatol. 2022, 142:459-468.e15. 10.1016\/j.jid.2021.05.036","journal-title":"J Invest Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-1-70","article-title":"Hidradenitis suppurativa: an update","volume":"16","author":"Ingram JR","year":"2016","unstructured":"Ingram JR. Hidradenitis suppurativa: an update. Clin Med (Lond). 2016, 16:70-3. 10.7861\/clinmedicine.16-1-70","journal-title":"Clin Med (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.13678","article-title":"The role of negative-pressure wound therapy in the management of axillary hidradenitis suppurativa","volume":"19","author":"Ezanno AC","year":"2022","unstructured":"Ezanno AC, Fougerousse AC, Guillem P. The role of negative-pressure wound therapy in the management of axillary hidradenitis suppurativa. Int Wound J. 2022, 19:802-10. 10.1111\/iwj.13678","journal-title":"Int Wound J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2014.07.012","article-title":"Hidradenitis suppurativa","volume":"28","author":"Margesson LJ","year":"2014","unstructured":"Margesson LJ, Danby FW. Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol. 2014, 28:1013-27. 10.1016\/j.bpobgyn.2014.07.012","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis CC","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, et al.. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015, 29:619-44. 10.1111\/jdv.12966","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00667-8","article-title":"Medical management of hidradenitis suppurativa with non-biologic therapy: what's new?","volume":"23","author":"Ghanian S","year":"2022","unstructured":"Ghanian S, Yamanaka-Takaichi M, Naik HB, Alavi A. Medical management of hidradenitis suppurativa with non-biologic therapy: what's new?. Am J Clin Dermatol. 2022, 23:167-76. 10.1007\/s40257-021-00667-8","journal-title":"Am J Clin Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan A","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et al.. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019, 81:76-90. 10.1016\/j.jaad.2019.02.067","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000524121","article-title":"Intralesional treatments in hidradenitis suppurativa: a systematic review","volume":"238","author":"Cuenca-Barrales C","year":"2022","unstructured":"Cuenca-Barrales C, Montero-V\u00edlchez T, S\u00e1nchez-D\u00edaz M, et al.. Intralesional treatments in hidradenitis suppurativa: a systematic review. Dermatology. 2022, 238:1084-91. 10.1159\/000524121","journal-title":"Dermatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2017.017","article-title":"Pathophysiology of hidradenitis suppurativa","volume":"36","author":"Hoffman LK","year":"2017","unstructured":"Hoffman LK, Ghias MH, Lowes MA. Pathophysiology of hidradenitis suppurativa. Semin Cutan Med Surg. 2017, 36:47-54. 10.12788\/j.sder.2017.017","journal-title":"Semin Cutan Med Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14141","article-title":"A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa","volume":"30","author":"Williams SC","year":"2021","unstructured":"Williams SC, Frew JW, Krueger JG. A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa. Exp Dermatol. 2021, 30:1388-97. 10.1111\/exd.14141","journal-title":"Exp Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S199862","article-title":"Systematic review of immunomodulatory therapies for hidradenitis suppurativa","volume":"13","author":"Lim SY","year":"2019","unstructured":"Lim SY, Oon HH. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics. 2019, 13:53-78. 10.2147\/BTT.S199862","journal-title":"Biologics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228436","article-title":"Cytokine pathways and investigational target therapies in hidradenitis suppurativa","volume":"21","author":"Del Duca E","year":"2020","unstructured":"Del Duca E, Morelli P, Bennardo L, Di Raimondo C, Nistic\u00f2 SP. Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int J Mol Sci. 2020, 21:8436. 10.3390\/ijms21228436","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4097574","article-title":"MMP8 is increased in lesions and blood of acne inversa patients: a potential link to skin destruction and metabolic alterations","volume":"2016","author":"Tsaousi A","year":"2016","unstructured":"Tsaousi A, Witte E, Witte K, et al.. MMP8 is increased in lesions and blood of acne inversa patients: a potential link to skin destruction and metabolic alterations. Mediators Inflamm. 2016, 2016:4097574. 10.1155\/2016\/4097574","journal-title":"Mediators Inflamm"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis CC","year":"2019","unstructured":"Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al.. Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019, 33:19-31. 10.1111\/jdv.15233","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2513","article-title":"Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group","volume":"97","author":"Horv\u00e1th B","year":"2016","unstructured":"Horv\u00e1th B, Janse IC, Blok JL, et al.. Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group. Acta Derm Venereol. 2016, 97:412-3. 10.2340\/00015555-2513","journal-title":"Acta Derm Venereol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/12034754211024157","article-title":"Hidradenitis suppurativa from a patient perspective including symptoms and self-treatment","volume":"25","author":"Huang CM","year":"2021","unstructured":"Huang CM, Kirchhof MG. Hidradenitis suppurativa from a patient perspective including symptoms and self-treatment. J Cutan Med Surg. 2021, 25:591-7. 10.1177\/12034754211024157","journal-title":"J Cutan Med Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1800","article-title":"The influence of body weight on the prevalence and severity of hidradenitis suppurativa","volume":"94","author":"Kromann CB","year":"2014","unstructured":"Kromann CB, Ibler KS, Kristiansen VB, Jemec GB. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014, 94:553-7. 10.2340\/00015555-1800","journal-title":"Acta Derm Venereol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius K","year":"2009","unstructured":"Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009, 161:831-9. 10.1111\/j.1365-2133.2009.09198.x","journal-title":"Br J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14870","article-title":"Comprehensive approach to managing hidradenitis suppurativa patients","volume":"59","author":"Collier EK","year":"2020","unstructured":"Collier EK, Hsiao JL, Shi VY, Naik HB. Comprehensive approach to managing hidradenitis suppurativa patients. Int J Dermatol. 2020, 59:744-7. 10.1111\/ijd.14870","journal-title":"Int J Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen OJ","year":"1983","unstructured":"Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983, 22:325-8. 10.1111\/j.1365-4362.1983.tb02150.x","journal-title":"Int J Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12459","article-title":"New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study","volume":"40","author":"Fadel MA","year":"2015","unstructured":"Fadel MA, Tawfik AA. New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study. Clin Exp Dermatol. 2015, 40:116-22. 10.1111\/ced.12459","journal-title":"Clin Exp Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03377.x","article-title":"Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa","volume":"35","author":"Boer J","year":"2010","unstructured":"Boer J, Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol. 2010, 35:36-40. 10.1111\/j.1365-2230.2009.03377.x","journal-title":"Clin Exp Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19337","article-title":"Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance","volume":"183","author":"Molinelli E","year":"2020","unstructured":"Molinelli E, Brisigotti V, Simonetti O, et al.. Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance. Br J Dermatol. 2020, 183:1117-9. 10.1111\/bjd.19337","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec GB","year":"1998","unstructured":"Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998, 39:971-4. 10.1016\/s0190-9622(98)70272-5","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12933","article-title":"Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up","volume":"41","author":"Dessinioti C","year":"2016","unstructured":"Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol. 2016, 41:852-7. 10.1111\/ced.12933","journal-title":"Clin Exp Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan A","year":"2009","unstructured":"Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009, 60:539-61. 10.1016\/j.jaad.2008.11.911","journal-title":"J Am Acad Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14119","article-title":"Spironolactone therapy for hidradenitis suppurativa","volume":"45","author":"Quinlan C","year":"2020","unstructured":"Quinlan C, Kirby B, Hughes R. Spironolactone therapy for hidradenitis suppurativa. Clin Exp Dermatol. 2020, 45:464-5. 10.1111\/ced.14119","journal-title":"Clin Exp Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball AB","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al.. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016, 375:422-34. 10.1056\/NEJMoa1504370","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant A","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010, 62:205-17. 10.1016\/j.jaad.2009.06.050","journal-title":"J Am Acad Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.06.049","article-title":"Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series","volume":"75","author":"Riis PT","year":"2016","unstructured":"Riis PT, Boer J, Prens EP, et al.. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol. 2016, 75:1151-5. 10.1016\/j.jaad.2016.06.049","journal-title":"J Am Acad Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8018192","article-title":"Review of current immunologic therapies for hidradenitis suppurativa","volume":"2017","author":"Shanmugam VK","year":"2017","unstructured":"Shanmugam VK, Zaman NM, McNish S, Hant FN. Review of current immunologic therapies for hidradenitis suppurativa. Int J Rheumatol. 2017, 2017:8018192. 10.1155\/2017\/8018192","journal-title":"Int J Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.043","article-title":"New and traditional surgical approaches to hidradenitis suppurativa","volume":"73","author":"Danby FW","year":"2015","unstructured":"Danby FW, Hazen PG, Boer J. New and traditional surgical approaches to hidradenitis suppurativa. J Am Acad Dermatol. 2015, 73:S62-5. 10.1016\/j.jaad.2015.07.043","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/178194-hidradenitis-suppurativa-a-literature-review-comparing-current-therapeutic-modalities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:27Z","timestamp":1707509067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/178194-hidradenitis-suppurativa-a-literature-review-comparing-current-therapeutic-modalities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.43695","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,18]]}}}